» Articles » PMID: 26755784

Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations

Overview
Journal Ann Fam Med
Specialty Public Health
Date 2016 Jan 13
PMID 26755784
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Recent results suggests the risk of a new onset of depression increases with longer duration of opioid analgesic use. It is unclear whether new-onset depression related to opioid analgesic use is a function of the dose prescribed or the duration of use or both.

Methods: Using a retrospective cohort design, we collected patient data from 2000 to 2012 from the Veterans Health Administration (VHA), and from 2003 to 2012 from both Baylor Scott & White Health (BSWH) and the Henry Ford Health System (HFHS). Patients (70,997 VHA patients, 13,777 BSWH patients, and 22,981 HFHS patients) were new opioid users, aged 18 to 80 years, without a diagnosis of depression at baseline. Opioid analgesic use duration was defined as 1 to 30, 31 to 90, and more than 90 days, and morphine equivalent dose (MED) was defined as 1 to 50 mg/d, 51 to 100 mg/d, and greater than 100 mg/d of analgesic. Pain and other potential confounders were controlled for by inverse probability of treatment-weighted propensity scores.

Results: New-onset depression after opioid analgesic use occurred in 12% of the VHA sample, 9% of the BSWH sample, and 11% of the HFHS sample. Compared with 1- to 30-day users, new-onset depression increased in those with longer opioid analgesic use. Risk of new-onset depression with 31 to 90 days of opioid analgesic use ranged from hazard ratio [HR] = 1.18 (95% CI, 1.10-1.25) in VHA to HR = 1.33 (95% CI, 1.16-1.52) in HFHS; in opioid analgesic use of more than 90 days, it ranged from HR = 1.35 (95% CI, 1.26-1.44) in VHA to HR = 2.05 (95% CI, 1.75-2.40) in HFHS. Dose was not significantly associated with a new onset of depression.

Conclusions: Opioid-related new onset of depression is associated with longer duration of use but not dose. Patients and practitioners should be aware that opioid analgesic use of longer than 30 days imposes risk of new-onset depression. Opioid analgesic use, not just pain, should be considered a potential source when patients report depressed mood.

Citing Articles

The contribution of nonmedical opioid use to healthcare encounters for opioid overdose and use disorders among long-term users with metastatic cancer.

Hannah H, Harsanyi H, Lin Y, Yang L, Jenny L, Lau J Support Care Cancer. 2024; 33(1):27.

PMID: 39672945 DOI: 10.1007/s00520-024-09082-1.


The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials.

Azari L, Hemati H, Tavasolian R, Shahdab S, Tomlinson S, Babilonia M Healthcare (Basel). 2024; 12(16).

PMID: 39201120 PMC: 11354190. DOI: 10.3390/healthcare12161560.


The Impact of Nonpharmacological Interventions on Opioid Use for Chronic Noncancer Pain: A Scoping Review.

Coffee Z, Cheng K, Slebodnik M, Mulligan K, Yu C, Vanderah T Int J Environ Res Public Health. 2024; 21(6).

PMID: 38929040 PMC: 11203961. DOI: 10.3390/ijerph21060794.


The interplay between the microbiota and opioid in the treatment of neuropathic pain.

Gong Z, Xue Q, Luo Y, Yu B, Hua B, Liu Z Front Microbiol. 2024; 15:1390046.

PMID: 38919504 PMC: 11197152. DOI: 10.3389/fmicb.2024.1390046.


Does opioid therapy enhance quality of life in patients suffering from chronic non-malignant pain? A systematic review and meta-analysis.

Kraft K, Backmund T, Eberhart L, Schubert A, Dinges H, Hagen M Br J Pain. 2024; 18(3):227-242.

PMID: 38751560 PMC: 11092930. DOI: 10.1177/20494637231216352.


References
1.
Sullivan M, Edlund M, Zhang L, Unutzer J, Wells K . Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006; 166(19):2087-93. DOI: 10.1001/archinte.166.19.2087. View

2.
Younger J, Chu L, DArcy N, Trott K, Jastrzab L, Mackey S . Prescription opioid analgesics rapidly change the human brain. Pain. 2011; 152(8):1803-1810. PMC: 3138838. DOI: 10.1016/j.pain.2011.03.028. View

3.
Psaty B, Koepsell T, Lin D, Weiss N, Siscovick D, Rosendaal F . Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999; 47(6):749-54. DOI: 10.1111/j.1532-5415.1999.tb01603.x. View

4.
Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J . Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain. 2010; 133(Pt 7):2098-114. PMC: 2912691. DOI: 10.1093/brain/awq138. View

5.
Frayne S, Miller D, Sharkansky E, Jackson V, Wang F, Halanych J . Using administrative data to identify mental illness: what approach is best?. Am J Med Qual. 2009; 25(1):42-50. DOI: 10.1177/1062860609346347. View